Ultragenyx Pharmaceutical Inc. Stock
Ultragenyx Pharmaceutical Inc. shows a slight decrease today, losing -€0.025 (-0.130%) compared to yesterday.
The stock is an absolute favorite of our community with 24 Buy predictions and no Sell predictions.
Based on the current price of 19.88 € the target price of 55 € shows a potential of 176.73% for Ultragenyx Pharmaceutical Inc. which would more than double the current price.
Pros and Cons of Ultragenyx Pharmaceutical Inc. in the next few years
Pros
?
C******** o* t** e**********
?
W********* I********* f** t** n*** y****
?
G***** c******* t* c**********
Cons
?
M***** P*******
?
B****
?
S********** s********
Tell us your opinion to access the 'Wisdom of the Crowds'
Performance of Ultragenyx Pharmaceutical Inc. vs. its peers
| Security | Change(%) | 1w | 1m | 1y | YTD | 3y | 5y |
|---|---|---|---|---|---|---|---|
| Ultragenyx Pharmaceutical Inc. | -0.130% | 1.606% | 5.430% | -34.195% | 16.726% | -44.290% | -77.329% |
| Ligand Pharmaceuticals | 0.550% | 1.676% | -0.546% | 97.826% | 9.639% | 177.863% | 49.425% |
| United Therapeutics | 0.760% | 0.327% | 4.602% | 98.224% | 14.908% | 138.813% | 194.012% |
| Ionis Pharmaceuticals Inc. | 1.150% | -1.696% | 2.246% | 167.478% | -6.210% | 86.866% | 85.398% |
Comments
Ultragenyx Pharmaceutical (RARE) had its price target lowered by JPMorgan Chase & Co. from $120.00 to $74.00. They now have an "overweight" rating on the stock.
Show more
Ratings data for RARE provided by MarketBeat
Ultragenyx Pharmaceutical (NASDAQ:RARE) had its price target lowered by analysts at Canaccord Genuity Group Inc. from $128.00 to $79.00. They now have a "buy" rating on the stock.
Show more
Ratings data for RARE provided by MarketBeat
Ultragenyx Pharmaceutical (NASDAQ:RARE) had its price target lowered by analysts at HC Wainwright from $60.00 to $50.00. They now have a "buy" rating on the stock.
Show more
Ratings data for RARE provided by MarketBeat
News
Why Ultragenyx Pharmaceutical Stock Is Bouncing Back Today
While Ultragenyx Pharmaceutical (NASDAQ: RARE) provided the market with disappointing news yesterday -- shares plunged more than 42% -- it appears that investors aren't completely writing off the
Why Ultragenyx Pharmaceuticals Stock Is Plummeting Today
Heading into 2026 on an inauspicious note, Ultragenyx Pharmaceuticals (NASDAQ: RARE), a pharmaceutical company specializing in treatments for rare and ultra-rare genetic diseases, announced